Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Alexander, Artyomenko"'
Autor:
Olga Glebova, Sergey Knyazev, Andrew Melnyk, Alexander Artyomenko, Yury Khudyakov, Alex Zelikovsky, Pavel Skums
Publikováno v:
BMC Genomics, Vol 18, Iss S10, Pp 81-88 (2017)
Abstract Background RNA viruses such as HCV and HIV mutate at extremely high rates, and as a result, they exist in infected hosts as populations of genetically related variants. Recent advances in sequencing technologies make possible to identify suc
Externí odkaz:
https://doaj.org/article/5074477777af4cdb8a4abca9314772fe
Publikováno v:
Endocrine Abstracts.
Autor:
Robert J, Pignolo, Miriam, Kimel, John, Whalen, Ariane K, Kawata, Alexander, Artyomenko, Frederick S, Kaplan
Publikováno v:
Bone. 168:116642
To assess the reliability and validity of age-specific versions of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ), developed to measure the impact of FOP on physical function and activities of daily living.FOP-PFQ
Autor:
Catalin Barbacioru, Jason Willis, M. Benavides, Marwan Fakih, Jinchul Kim, Jing Zhao, Kabir Mody, Timmy Nguyen, Richard B. Lanman, Jeeyun Lee, Seung Tae Kim, Kyoung-Mee Kim, Daniel V.T. Catenacci, Hyuk Lee, Yoshiaki Nakamura, Ramez N. Eskander, Nir Peled, Danielle Gavino, Darya Chudova, Scott Kopetz, Alexander Artyomenko, Pashtoon Murtaza Kasi, Takayuki Yoshino, Marcin Sikora, Victoria M. Raymond, Georges Azzi, Justin I. Odegaard, Stephen R. Fairclough, Martina I. Lefterova, Mike Cusnir, Kimberly C. Banks, Amir Ali Talasaz
Publikováno v:
Clinical Cancer Research. 25:7035-7045
Purpose:To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing.Experimental Design:Pan-cancer MSI detection using Guardant360 was analytically validated according to established guide
Autor:
Leslie A. Bucheit, Jennifer Yen, Leylah Drusbosky, Catalin Barbacioru, Sante Gnerre, Hao Wang, Alexander Artyomenko, Arielle Yabolonovitch, Yu Fu, Che-Yu Lee, Max Maliska, Elena Helman, Michael Dorshner, Martina Lefterova
Publikováno v:
Journal of Clinical Oncology. 40:180-180
180 Background: ctDNA testing is a non-invasive means to identify genomic alterations in patients with aPC, including BRCA1/2 and other HRR gene alterations, which are targetable by PARP inhibitors (PARPi). However, classes of HRR inactivating mutati
Autor:
Andrew Melnyk, Olga Glebova, Alexander Zelikovsky, Pavel Skums, Alexander Artyomenko, Sergey Knyazev, Yury Khudyakov
Publikováno v:
BMC Genomics, Vol 18, Iss S10, Pp 81-88 (2017)
BMC Genomics
BMC Genomics
Background RNA viruses such as HCV and HIV mutate at extremely high rates, and as a result, they exist in infected hosts as populations of genetically related variants. Recent advances in sequencing technologies make possible to identify such populat
Autor:
Alexander Artyomenko, Viachaslau Tsyvina, Andrew Melnyk, William M. Switzer, Sergey Knyazev, Pavel Skums, Tatiana Malygina, Serghei Mangul, Alexander Zelikovsky, Yuri B. Porozov, Anupama Shankar, Ellsworth M. Campbell
Rapidly evolving RNA viruses continuously produce minority haplotypes that can become dominant if they are drug-resistant or can better evade the immune system. Therefore, early detection and identification of minority viral haplotypes may help to pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4497153b55d0215c09433b88613c3d22
https://doi.org/10.1101/264242
https://doi.org/10.1101/264242
Autor:
Alexander Artyomenko, Pelin Icer Baykal, Pavel Skums, Alexander Zelikovsky, Yury Khudyakov, Sumathi Ramachandran
Publikováno v:
ICCABS
Hepatitis C virus (HCV) usually establishes chronic infection, which is often asymptomatic at the early stages of disease. Unfortunately, no diagnostic criteria that can distinguish between recent and chronic HCV infections are available. Error-prone
Autor:
Alexander Artyomenko, Alexander Zelikovsky, Pelin Burcak Icer, Pavel Skums, Sumathi Ramachandran, Yury Khudyakov
Publikováno v:
Bioinformatics Research and Applications ISBN: 9783319595740
ISBRA
ISBRA
Intra-host genetic diversity of hepatitis C virus (HCV) plays crucial role in disease progression and treatment outcome. Development of new treatment strategies, generation and validation of new biomedical hypothesis, development of algorithms and mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddbfaddd216b0b764fb42ccf17a60440
https://doi.org/10.1007/978-3-319-59575-7_45
https://doi.org/10.1007/978-3-319-59575-7_45
Autor:
Stephen R. Fairclough, AmirAli Talasaz, Alexander Artyomenko, Jing Zhao, John H. Strickler, Catalin Barbacioru, Richard B. Lanman, Elena Helman, John A. Latham, Darya Chudova, Carlo Artieri
Publikováno v:
Cancer Research. 79:1675-1675
Background: Late stage therapy selection is advancing beyond the detection of classical driver alterations (SNV, Indel, CNV, Fusion) to the use of aggregate biomarkers comprising combinations of SNVs, Indels, and fusions, that reflect the underlying